MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress

What happened: Moderna $MRNA and Merck $MRK reported detailed positive phase III INTerpath-001 results for intismeran autogene plus Keytruda in resected high-risk melanoma, disclosed on Oct. 22 after a data leak ahead of the ESMO presentation. Key numbers: Median follow-up 24.6 months. Why it matters: The sell-off was described as a possible sell-the-news reaction, with investors comparing results to phase IIb data and weighing elevated expectations. Overall survival data remain immature and regulatory timelines uncertain. Market: +0.8% today ($125.52), +78.5% YTD, 0.2x vol — as of 17:02 UTC

Moderna $MRNA and Merck $MRK reported detailed positive phase III INTerpath-001 results for intismeran autogene plus Keytruda in resected high-risk melanoma, disclosed on Oct. 22 after a data leak ahead of the ESMO presentation.

The sell-off was described as a possible sell-the-news reaction, with investors comparing results to phase IIb data and weighing elevated expectations. Overall survival data remain immature and regulatory timelines uncertain. Market: +0.8% today ($125.52), +78.5% YTD, 0.2x vol — as of 17:02 UTC